MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Cytosorbents Corporation EPS Ratio 2011-2026 | CTSO
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Cytosorbents Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.38 | -0.65 | -0.02 | -0.25 | -0.2 | -0.6 | -0.56 | -0.32 | -0.47 | -0.33 | -1.29 | -0.03 | -0.03 | -0.05 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.02 | -1.29 | -0.37 |
Quarterly EPS Ratio Cytosorbents Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | 0.03 | -0.02 | - | -0.05 | -0.08 | -0.11 | - | -0.21 | -0.14 | -0.17 | - | -0.28 | -0.25 | -0.21 | -0.25 | -0.15 | -0.11 | -0.1 | - | -0.02 | -0.08 | -0.1 | -0.13 | -0.21 | -0.11 | -0.15 | -0.17 | -0.1 | -0.19 | -0.1 | -0.12 | -0.07 | -0.07 | -0.06 | -0.19 | -0.09 | -0.12 | -0.07 | -0.08 | -0.11 | 0.06 | -0.19 | -0.84 | -0.22 | -0.27 | -0.2 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.06 | -0.84 | -0.12 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Medical devices industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
-2.81 | - | -26.83 % | $ 2.62 M |  USA |
 |
Allied Healthcare Products
AHPI
|
-0.48 | - | 3.58 % | $ 2.21 M | USA |
 |
Avinger
AVGR
|
-23.3 | - | -20.74 % | $ 369 K | USA |
 |
Aziyo Biologics
AZYO
|
1.29 | - | 1.37 % | $ 20.5 M | USA |
 |
Cutera
CUTR
|
-2.87 | - | -10.19 % | $ 1.99 M | USA |
 |
BIOLASE
BIOL
|
-29.4 | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-6.99 | - | - | $ 16.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-0.98 | - | - | $ 475 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.43 | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-1.28 | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
-2 | - | -0.57 % | $ 7.12 M | USA |
 |
Aethlon Medical
AEMD
|
-8.58 | $ 2.22 | -0.89 % | $ 3.47 M | USA |
 |
InspireMD
NSPR
|
-0.76 | $ 1.74 | -2.79 % | $ 112 M |  Israel |
 |
AdaptHealth Corp.
AHCO
|
-0.52 | $ 9.97 | -4.78 % | $ 1.35 B | USA |
 |
BioSig Technologies
BSGM
|
-0.75 | - | 37.08 % | $ 85.7 M | USA |
 |
Second Sight Medical Products
EYES
|
-0.43 | - | -0.97 % | $ 54.4 M | USA |
 |
Invacare Corporation
IVC
|
-0.54 | - | - | $ 24.7 M | USA |
 |
TELA Bio
TELA
|
-2.04 | $ 0.8 | 10.42 % | $ 18.3 M | USA |
 |
Align Technology
ALGN
|
5.63 | $ 177.25 | 2.81 % | $ 13.3 B | USA |
 |
Alphatec Holdings
ATEC
|
-0.96 | $ 12.54 | -0.16 % | $ 1.88 B | USA |
 |
AxoGen
AXGN
|
-0.34 | $ 30.55 | -1.26 % | $ 1.41 B | USA |
 |
Butterfly Network
BFLY
|
-0.34 | $ 3.99 | 1.01 % | $ 845 M | USA |
 |
Bio-Rad Laboratories
BIO
|
-25.6 | $ 265.81 | -0.81 % | $ 7.5 B | USA |
 |
Bruker Corporation
BRKR
|
0.76 | $ 33.79 | -0.71 % | $ 5.04 K | USA |
 |
Boston Scientific Corporation
BSX
|
1.96 | $ 71.21 | -0.1 % | $ 105 B | USA |
 |
Cardiovascular Systems
CSII
|
-0.94 | - | 0.15 % | $ 844 M | USA |
 |
ClearPoint Neuro
CLPT
|
-0.9 | $ 9.17 | -4.53 % | $ 260 M | USA |
 |
CONMED Corporation
CNMD
|
1.52 | $ 36.79 | 0.22 % | $ 1.14 B | USA |
 |
Inari Medical
NARI
|
-0.55 | - | - | $ 4.23 B | USA |
 |
Eargo
EAR
|
-39.7 | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
0.08 | $ 9.37 | -0.11 % | $ 336 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-0.51 | $ 4.02 | 2.55 % | $ 150 M |  France |
 |
Electromed
ELMD
|
0.89 | $ 23.47 | 1.29 % | $ 198 M | USA |
 |
NuVasive
NUVA
|
0.78 | - | - | $ 2.07 B | USA |
 |
Establishment Labs Holdings
ESTA
|
-1.72 | $ 66.01 | 0.78 % | $ 1.96 B |  Costa-rica |
 |
Nevro Corp.
NVRO
|
-3.06 | - | - | $ 217 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.84 | $ 82.92 | 0.38 % | $ 48.5 B | USA |
 |
FONAR Corporation
FONR
|
1.78 | $ 18.44 | - | $ 121 M | USA |